About Oncostem diagnostics pvt ltd
Oncostem Diagnostics Pvt Ltd: Revolutionizing Breast Cancer Diagnosis in India
Breast cancer is one of the most common types of cancer affecting women worldwide. In India, breast cancer is the most common type of cancer among women, accounting for 27% of all cancers. Early detection and accurate diagnosis are crucial for effective treatment and improved survival rates. However, traditional diagnostic methods such as mammography and biopsy have limitations in predicting the risk of recurrence and guiding personalized treatment plans.
Oncostem Diagnostics Pvt Ltd is a pioneering Indian biotech company that aims to revolutionize breast cancer diagnosis by providing innovative prognostic tests that can predict the risk of recurrence and guide personalized treatment plans. The company was founded in 2011 by Dr. Manjiri Bakre, a renowned scientist with over two decades of experience in oncology research.
Oncostem's flagship product is CanAssistBreast, a prognostic test that analyzes the molecular profile of breast tumors to predict their aggressiveness and likelihood of recurrence. CanAssistBreast uses advanced technology such as gene expression profiling to provide accurate results that can help doctors make informed decisions about treatment options.
CanAssistBreast has been validated through extensive clinical trials involving over 1,000 patients across India. The test has shown high accuracy in predicting the risk of recurrence among early-stage breast cancer patients, enabling doctors to identify those who may benefit from more aggressive treatments such as chemotherapy or radiation therapy.
In addition to CanAssistBreast, Oncostem also offers other diagnostic tests such as Tumour Test and Screening Test for breast cancer detection at an early stage when it's curable with minimal intervention.
Oncostem's commitment to innovation extends beyond its products; it also invests heavily in research and development activities aimed at improving existing tests' accuracy while developing new ones for other types of cancers like lung or prostate cancers.
Oncostem's success has not gone unnoticed, and the company has received several awards and recognitions for its innovative approach to breast cancer diagnosis. In 2019, Oncostem was awarded the prestigious Frost & Sullivan Indian Molecular Diagnostics Company of the Year Award.
Oncostem's mission is to make personalized cancer care accessible and affordable to all patients in India. The company aims to partner with hospitals and clinics across India to provide CanAssistBreast and other diagnostic tests at an affordable cost.
In conclusion, Oncostem Diagnostics Pvt Ltd is a game-changer in breast cancer diagnosis in India. Its innovative prognostic tests such as CanAssistBreast have shown high accuracy in predicting the risk of recurrence among early-stage breast cancer patients, enabling doctors to make informed decisions about treatment options. With its commitment to innovation and affordability, Oncostem is poised for continued success in improving cancer care outcomes for patients across India.